Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Nanoparticles of a Pyrazolo-Pyridazine Derivative as Potential EGFR and CDK-2 Inhibitors: Design, Structure Determination, Anticancer Evaluation and In Silico Studies.
Molecules ( IF 4.2 ) Pub Date : 2023-10-25 , DOI: 10.3390/molecules28217252 Heba E Hashem 1 , Abd El-Galil E Amr 2 , Abdulrahman A Almehizia 3 , Ahmed M Naglah 3 , Benson M Kariuki 4 , Heba A Eassa 5, 6 , Eman S Nossier 7, 8
Molecules ( IF 4.2 ) Pub Date : 2023-10-25 , DOI: 10.3390/molecules28217252 Heba E Hashem 1 , Abd El-Galil E Amr 2 , Abdulrahman A Almehizia 3 , Ahmed M Naglah 3 , Benson M Kariuki 4 , Heba A Eassa 5, 6 , Eman S Nossier 7, 8
Affiliation
The strategic planning of this study is based upon using the nanoformulation method to prepare nanoparticles 4-SLNs and 4-LPHNPs of the previously prepared 4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazin-3-amine (4) after confirming its structure with single crystal X-ray analysis. These nanoparticles exhibited promising cytotoxic activity against HepG-2, HCT-116 and MCF-7 cancer cell lines in comparison with the reference doxorubicin and the original derivative 4. Moreover, their inhibitory assessment against EGFR and CDK-2/cyclin A2 displayed improved and more favorable impact than the parent 4 and the references. Detection of their influence upon cancer biomarkers revealed upregulation of Bax, p53 and caspase-3 levels and downregulation of Bcl-2 levels. The docking simulation demonstrated that the presence of the pyrazolo[3,4-c]pyridazin-3-amine scaffold is amenable to enclosure and binding well within EGFR and CDK-2 receptors through different hydrophilic interactions. The pharmacokinetic and physicochemical properties of target 4 were also assessed with ADME investigation, and the outcome indicated good drug-like characteristics.
中文翻译:
作为潜在 EGFR 和 CDK-2 抑制剂的吡唑并哒嗪衍生物纳米颗粒:设计、结构测定、抗癌评估和计算机研究。
本研究的战略规划是基于使用纳米制剂方法制备先前制备的4,5-二苯基-1H-吡唑并[3,4-c]哒嗪-3-胺(4 )通过单晶X射线分析确认其结构后。与参考阿霉素和原始衍生物 4 相比,这些纳米颗粒对 HepG-2、HCT-116 和 MCF-7 癌细胞系表现出有希望的细胞毒活性。此外,它们对 EGFR 和 CDK-2/cyclin A2 的抑制评估显示出改善和改善。比母体4和参考文献产生更有利的影响。检测它们对癌症生物标志物的影响揭示了 Bax、p53 和 caspase-3 水平的上调以及 Bcl-2 水平的下调。对接模拟表明,吡唑并[3,4-c]哒嗪-3-胺支架的存在易于通过不同的亲水相互作用在EGFR和CDK-2受体内封装和结合。还通过 ADME 研究评估了靶标 4 的药代动力学和理化性质,结果表明具有良好的药物样特性。
更新日期:2023-10-25
中文翻译:
![](https://scdn.x-mol.com/jcss/images/paperTranslation.png)
作为潜在 EGFR 和 CDK-2 抑制剂的吡唑并哒嗪衍生物纳米颗粒:设计、结构测定、抗癌评估和计算机研究。
本研究的战略规划是基于使用纳米制剂方法制备先前制备的4,5-二苯基-1H-吡唑并[3,4-c]哒嗪-3-胺(4 )通过单晶X射线分析确认其结构后。与参考阿霉素和原始衍生物 4 相比,这些纳米颗粒对 HepG-2、HCT-116 和 MCF-7 癌细胞系表现出有希望的细胞毒活性。此外,它们对 EGFR 和 CDK-2/cyclin A2 的抑制评估显示出改善和改善。比母体4和参考文献产生更有利的影响。检测它们对癌症生物标志物的影响揭示了 Bax、p53 和 caspase-3 水平的上调以及 Bcl-2 水平的下调。对接模拟表明,吡唑并[3,4-c]哒嗪-3-胺支架的存在易于通过不同的亲水相互作用在EGFR和CDK-2受体内封装和结合。还通过 ADME 研究评估了靶标 4 的药代动力学和理化性质,结果表明具有良好的药物样特性。